HC Wainwright reissued their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a research report released on Wednesday morning, AnalystRatings.com reports. HC Wainwright currently has a $72.00 price target on the stock.
Several other analysts also recently issued reports on the company. JPMorgan Chase & Co. upgraded G1 Therapeutics from a neutral rating to an overweight rating and boosted their price objective for the stock from $38.00 to $45.00 in a report on Thursday, August 8th. Cowen restated a buy rating on shares of G1 Therapeutics in a report on Monday, September 30th. Zacks Investment Research upgraded G1 Therapeutics from a sell rating to a hold rating in a report on Saturday, November 2nd. Needham & Company LLC set a $74.00 price objective on G1 Therapeutics and gave the stock a buy rating in a report on Monday, September 30th. Finally, BidaskClub downgraded G1 Therapeutics from a buy rating to a hold rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the stock. G1 Therapeutics currently has a consensus rating of Buy and an average price target of $56.67.
Shares of GTHX traded up $0.20 during mid-day trading on Wednesday, reaching $23.68. 223,300 shares of the stock traded hands, compared to its average volume of 399,541. The stock has a fifty day simple moving average of $24.51 and a 200 day simple moving average of $26.43. G1 Therapeutics has a 12-month low of $13.87 and a 12-month high of $46.50. The firm has a market cap of $839.76 million, a price-to-earnings ratio of -9.25 and a beta of 2.21.
A number of large investors have recently added to or reduced their stakes in the business. California Public Employees Retirement System grew its stake in G1 Therapeutics by 113.2% during the 3rd quarter. California Public Employees Retirement System now owns 67,162 shares of the company’s stock valued at $1,530,000 after acquiring an additional 35,662 shares in the last quarter. Rhumbline Advisers grew its stake in G1 Therapeutics by 4.0% during the 3rd quarter. Rhumbline Advisers now owns 45,839 shares of the company’s stock valued at $1,044,000 after acquiring an additional 1,783 shares in the last quarter. Tuttle Tactical Management purchased a new position in G1 Therapeutics during the 3rd quarter valued at about $1,603,000. Nisa Investment Advisors LLC grew its stake in G1 Therapeutics by 4,953.6% during the 3rd quarter. Nisa Investment Advisors LLC now owns 25,268 shares of the company’s stock valued at $576,000 after acquiring an additional 24,768 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB grew its stake in G1 Therapeutics by 95.3% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 535,657 shares of the company’s stock valued at $12,202,000 after acquiring an additional 261,383 shares in the last quarter. 76.63% of the stock is currently owned by institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.
Recommended Story: What is a stock portfolio tracker?
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.